Leaflet: information for the user
Vizarsin 100 mg film-coated tablets
sildenafil
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Vizarsin contains the active ingredient sildenafilo, which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by dilating the blood vessels of the penis, allowing blood to flow when sexually stimulated. Vizarsin will only help you achieve an erection if you are sexually stimulated.
Vizarsin is indicated for the treatment of erectile dysfunction in adult men, sometimes referred to as impotence. This occurs when a man is unable to obtain or maintain a firm, satisfactory erection for sexual activity.
Do not take Vizarsin
Warnings and precautions
Consult your doctor or pharmacist before starting to take Vizarsin:
Do not use Vizarsin simultaneously with any other oral or local treatment for erectile dysfunction.
Do not take Vizarsin with treatments for pulmonary arterial hypertension (PAH) that contain sildenafil or any other PDE5 inhibitor.
Do not take Vizarsin if you do not have erectile dysfunction.
Use of Vizarsin is not indicated in women.
Special considerations in patients with renal or hepatic problems
You must inform your doctor if you have renal or hepatic problems. Your doctor may decide to reduce your dose.
Children and adolescents
Use of Vizarsin is not indicated in individuals under 18 years of age.
Use of Vizarsin with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Vizarsin tablets may interact with some medications, especially those used to treat chest pain. In case of a medical emergency, you must inform your doctor, pharmacist, or nurse that you are taking Vizarsin and when you took it. Do not take Vizarsin with other medications unless your doctor advises you to.
Do not take Vizarsin if you are taking medications called nitrates, as the combination may lead to a dangerous drop in your blood pressure. Always inform your doctor, pharmacist, or nurse if you are taking any of these medications, which are often used to relieve chest pain (or "chest pain").
Do not take Vizarsin if you are taking medications called nitric oxide donors, such as amyl nitrite ("poppers"), as the combination may also lead to a dangerous drop in your blood pressure. Inform your doctor or pharmacist if you are taking riociguat.
If you are taking medications known as protease inhibitors, such as those used to treat HIV, your doctor may recommend that you start treatment with the lowest dose (25 mg) of Vizarsin.
Some patients taking an alpha-blocker, a medication used to treat high blood pressure or prostate enlargement, may experience dizziness or lightheadedness that may be caused by a drop in blood pressure when sitting or standing up quickly. Some patients have experienced these symptoms when taking Vizarsin with alpha-blockers. This is more likely to occur in the 4 hours following Vizarsin intake. To reduce the likelihood of these symptoms, you should be receiving your daily dose of the alpha-blocker regularly before starting Vizarsin. Your doctor may recommend that you start treatment with the lower dose (25 mg) of Vizarsin.
Use of Vizarsin with food, drinks, and alcohol
Vizarsin can be taken with or without food. However, you may notice that Vizarsin takes a little longer to take effect if taken with a large meal.
Consuming alcohol may temporarily impair your ability to achieve an erection. Therefore, to get the maximum benefit from the medication, it is recommended not to consume large amounts of alcohol before taking Vizarsin.
Pregnancy, breastfeeding, and fertility
Use of Vizarsin is not indicated in women.
Driving and operating machinery
Vizarsin may cause dizziness and affect vision. You must know how you react to Vizarsin before driving vehicles or operating machinery.
Vizarsin contains lactose and sodium
If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended starting dose is 50 mg.
Do not take Vizarsin more than once a day.
Take Vizarsin approximately one hour before planning to have sexual intercourse. Swallow the tablet whole with a glass of water.
If you notice that the effect of Vizarsin is too strong or too weak, inform your doctor or pharmacist.
Vizarsin will only help you achieve an erection if you are sexually stimulated. The time it takes for Vizarsin to take effect varies from person to person, generally ranging from half an hour to one hour. The effect of Vizarsin may be delayed if taken with a large meal.
If Vizarsin does not help you achieve an erection or if the erection does not last long enough to complete sexual intercourse, consult your doctor.
If you take more Vizarsin than you should
You may experience an increase in adverse effects and their severity. Doses above 100 mg do not increase efficacy.
Do not take more tablets than recommended by your doctor.
Contact your doctor if you have taken more tablets than advised.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The side effects reported associated with the use of Vizarsin are generally of mild to moderate intensity and short duration.
If you experience any of the following serious side effects, stop taking Vizarsin and seek medical attention immediately:
The symptoms include sudden hissing while breathing, difficulty breathing or dizziness, swelling of the eyelids, face, lips, or throat.
If they occur during or after sexual intercourse:
If you have an erection that lasts more than 4 hours, you must contact your doctor immediately.
The symptoms may include severe peeling and swelling of the skin, vesiculation of the mouth, genitals, and around the eyes, as well as fever.
Other side effects:
Very common(may affect more than 1 in 10 people): headache.
Common(may affect up to 1 in 10 people): nausea, facial flushing, warmth (including symptoms such as sudden heat in the upper body), indigestion, abnormal color perception, blurred vision, visual deterioration, nasal congestion, and dizziness.
Uncommon(may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, eye discharge/ red eyes, eye pain, flashing lights vision, visual clarity, light sensitivity, watery eyes, palpitations, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling of drowsiness, reduced tactile sensation, vertigo, ringing in the ears, dry mouth, nasal congestion or blockage, nasal mucosa inflammation (including symptoms such as sneezing, runny nose, and nasal congestion), upper abdominal pain, gastroesophageal reflux disease (including symptoms such as stomach burning), blood in urine, arm or leg pain, nosebleed, feeling of heat, and feeling tired.
Rare(may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, transient decrease in blood flow to some parts of the brain, sensation of throat constriction, numbness of the mouth, bleeding in the back of the eye, double vision, visual acuity decrease, abnormal sensation in the eye, eye swelling or eyelid swelling, small particles or spots in vision, halos around lights, pupil dilation, change in color of the white part of the eye, penile bleeding, blood in semen, dry nose, nasal swelling, sensation of irritability, and sudden decrease or loss of hearing.
During post-marketing experience, rare cases of unstable angina (heart disease) and sudden death have been reported. It is worth noting that most men who experienced these side effects, although not all of them, had heart problems before taking this medicine. It is not possible to determine if these side effects were directly related to Vizarsin.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through thenational notification system included in Appendix V.By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the box after EXP. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Vizarsin
Core of the tablet: | Microcrystalline cellulose (E460), calcium hydrogen phosphate, croscarmellose sodium, hypromellose (E464), magnesium stearate (E470b). |
Film coating: | Film coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518). |
See section 2 “Vizarsin contains lactose and sodium”.
Appearance of the product and contents of the pack
Vizarsin 100 mg film-coated tablets are white, oblong and have “100” engraved on one side.
Vizarsin 100 mg film-coated tablets are available in packs of 1 film-coated tablet in a blister pack and also in packs of 4 x 1, 8 x 1 or 12 x 1 film-coated tablets in perforated unit dose blisters.
Only some pack sizes may be marketed.
Marketing authorization holder and responsible person for manufacturing
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien KRKA Belgium, SA. Tél/Tel: + 32 (0) 487 50 73 62 | Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Luxembourg/Luxemburg KRKA Belgium, SA. Tél/Tel: + 32 (0) 487 50 73 62 (BE) | |
Ceská republika KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Magyarország KRKA Magyarország Kereskedelmi Kft. Tel.: + 36 (1) 355 8490 |
Danmark KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) | Malta E. J. Busuttil Ltd. Tel: + 356 21 445 885 |
Deutschland TADPharma GmbH Tel: + 49 (0) 4721 606-0 | Nederland KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 | Norge KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) |
Ελλáδα KRKA ΕΛΛΑΣ ΕΠΕ Τηλ: + 30 2100101613 | Österreich KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
España KERN PHARMA, S.L. Tel: + 34 93 700 25 25 | Polska KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7500 |
France KRKA France Eurl Tél: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 650 |
Hrvatska KRKA - FARMA d.o.o. Tel: + 385 1 6312 100 | România KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3710 | Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Ísland LYFIS ehf. Sími: + 354 534 3500 | Slovenská republika KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italia KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Suomi/Finland KRKA Finland Oy Puh/Tel: + 358 20 754 5330 |
Κúπρος KI.PA. (PHARMACAL) LIMITED Τηλ: + 357 24 651 882 | Sverige KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvija KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: +353 1 413 3710 |
Date of the last review of this leaflet:
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.